Search Within

Advanced Practice Providers

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (36)
  2. Journal Article (14)
Groups
  1. Center for Hematologic Malignancies (50)
  2. Department of Medicine (50)
  3. Hematologic Malignancies, Division of (50)
  4. Lymphoma (50)
  5. Population Sciences Research Program (41)
  6. Survivorship Research (34)

More Groups

People
  1. Alison Moskowitz (50)
  2. Steven Horwitz (41)
  3. Andrew Zelenetz (34)
  4. Ariela Noy (32)
  5. Paul Hamlin (29)
  6. Anita Kumar (28)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (6)
  4. 2022 (2)
  5. 2021 (5)
  6. 2020 (4)

More Years

Publications
  1. Blood (27)
  2. Journal of Clinical Oncology (7)
  3. Hematological Oncology (5)
  4. Annals of Oncology (2)
  5. Leukemia and Lymphoma (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (27)
  2. American Society of Clinical Oncology (7)
  3. Wiley Blackwell (5)
  4. Oxford University Press (2)
  5. Taylor & Francis Group (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Bantilan, K. S.; Verwys, S. L.; McCall, S. J.; Yahalom, J.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma
    Meeting Abstract

    Mehta-Shah, N; Lunning, M. A.; Boruchov, A. M.; Ruan, J.; Nair, S.; Lynch, P.; Byrne, R.; Moskowitz, A. J.; Matasar, M. J.; Gerecitano, J. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Hamlin, P. A. Jr; Perales, M. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • Updated results of a phase II trial of bendamustine in relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Hamlin, P.; Gerecitano, J.; Horwitz, S.; Matasar, M.; Noy, A.; Palomba, M. L.; Portlock, C.; Straus, D.; Graustein, T.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save